Press Release

Lee's Pharm Announces 2019 Third Quarterly Results Nov 28, 2019 21:22 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its unaudited consolidated quarterly financial results for the nine months ended 30 September 2019 (the "period under review"). More info..

COPFL announced that its wholly-owned subsidiary-ZKO, has successfully completed a Phase II trial of Cyclosporine A Ophthalmic Gel
Oct 31, 2019 11:10 JST

China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO"), has successfully completed a Phase II trial of Cyclosporine A (CsA) Ophthalmic Gel in China (clinicaltrials.gov registration No.:NCT03676335). Topline data show that the experimental drug has similar or a trend towards better efficacy than that of the marketed CsA Ophthalmic Emulsion.
More info..

Lee's Pharm Announces 2018 Annual Results Mar 28, 2019 19:46 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its annual results for the year ended 31 December 2018 (the "year under review"). More info..

Lee's Pharm Announces 2017 Third Quarterly Results Nov 23, 2017 18:12 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven an market-oriented pharmaceutical group in China, today announced its unaudited consolidated quarterly financial results (the "Quarterly Results") for the nine months ended 30 September 2017 . More info..

Lee's Pharm Announces 2017 Interim Results Aug 24, 2017 23:29 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its interim results for the six months ended 30 June 2017 (the "period under review"). More info..

Lee's Pharm Announces 2016 Annual Results Mar 23, 2017 17:54 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its annual results for the year ended 31 December 2016 (the "year under review"). More info..

Lee's Pharm 2016 Interim Net Profit Up 17.9% Aug 25, 2016 19:00 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its unaudited interim results for the six months ended 30 June 2016 (the "period under review"). More info..

Lee's Pharm Announces 2015 Annual Results Mar 23, 2016 17:39 JST Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its annual results for the year ended 31 December 2015 (the "year under review"). More info..

Lee's Pharmaceutical Enters into Agreement with Nippon Shinyaku, a Move To Accelerate Market Diversification in China
Mar 03, 2009 13:31 JST

Hong Kong Lee's Pharmaceutical Holdings Limited, an integrated research-driven and market-oriented pharmaceutical group in China, announced today a signing of a license agreement with Nippon Shinyaku Co., Ltd., a listed pharmaceutical company in Japan, for the pharmaceutical product containing Nippon Shinyakua's antibacterial agent "Prulifloxacin".
More info..